Clinical pharmacology of gonadotrophin preparations

Reproductive BioMedicine Online

Volumn 10, Issue SUPPL. 3, 2005, Pages 19-24

  Ledger, William ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

GnRH agonists; GnRH antagonists; Gonadotrophins; Ovulation induction; Pharmacology

Indexed keywords

AROMATASE INHIBITOR; CHORIONIC GONADOTROPIN RECEPTOR; CLOMIFENE CITRATE; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LETROZOLE; METFORMIN; RECOMBINANT FOLLITROPIN;

ANOVULATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; HYPOGONADISM; LOW DRUG DOSE; MENSTRUAL CYCLE; META ANALYSIS; MULTIPLE PREGNANCY; NONHUMAN; OVARY CYCLE; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATIENT SATISFACTION; PREGNANCY; PREGNANCY RATE; REVIEW; SIDE EFFECT; SUPEROVULATION; SYSTEMATIC REVIEW;

EID: 22244483434     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(11)60386-6     Document Type: Article

References (48)

1. Aittomaki K, Herva R, Stenman UH et al. 1996 Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. Journal of Clinical Endocrinology and Metabolism 81, 3722-3726.
2. Albano C, Felberbaum RE, Smitz J et al. 2000 Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin, European Cetrorelix Study Group. Human Reproduction 15, 526-531.
3. Al-Inany H, Aboulghar M, Mansour R, Serour G 2003 Meta-analysis of recombinant versus urinary-derived FSH: an update. Human Reproduction 18, 305-313.
4. Baird DT 1987 A model for follicular selection and ovulation: lessons from superovulation. Journal of Steroid Biochemistry 27, 1.
5. Baker TC 1963 A quantitative and cytological study of germ cells in human ovaries. Proceedings of the Royal Society of Biology 158, 417.
6. Balen AH, Mulders AG, Fauser BC et al. 2004 Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. Journal of Clinical Endocrinology and Metabolism 89, 6297-6304.
7. Cédrin-Durnerin I, Grange-Dujardin D, Laffy A et al. 2004 Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Human Reproduction 19, 1979-1984.
8. Child TJ, Gulekli B, Abdul-Jalil AK, Tan SL 2001 In-vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with the polycystic ovarian syndrome. Fertility and Sterility 76, 936-942.
9. Coelingh Bennink HJ, Fauser BC, Out HJ 1998 Recombinant follicle stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group. Fertility and Sterility 69, 19-25.
10. Daya S, Gunby J 2000 Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews 4, CD002810.
11. European Middle East Orgalutran Study Group 2001 Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation, Human Reproduction 16, 644-651.
12. European Recombinant Human LH Study Group 1998 Recombinant human luteinizing hormone (LH) to support recombinant human follicle stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. Journal of Clinical Endocrinology and Metabolism 83, 1507-1514.
13. Faddy MJ, Gosden RG 1995 A mathematical model of follicle dynamics in the human ovary. Human Reproduction 10, 770-775.
14. Faddy MJ, Gosden RG 1996 A model conforming the decline in follicle numbers to the age of menopause in women. Human Reproduction 11, 1484-1486.
15. Fauser BC, Devroey P, Yen SS et al. 1999 Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Human Reproduction 14, 2681-2686.
16. Filicori M, Cognigni GE, Taraborrelli S et al. 1999 Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea. Fertility and Sterility 72, 1118-1120.
17. Fluker MR, Urman B, Mackinnon M et al. 1994 Exogenous gonadotropin therapy in World Health Organization groups I and II ovulatory disorders. Obstetrics and Gynecology 83, 189-196.
18. Franks S, White D 2002 Low-dose gonadotrophin treatment in polycystic ovary syndrome: the step-up protocol. In: Tarlatzis B (ed.) Ovulation Induction. Elsevier, Paris, pp. 98-107.
19. Ganirelix Dose-finding Study Group 1998 A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Human Reproduction 13, 3023-3303.
20. Gerli S, Casini ML, Unfer V et al. 2004 Ovulation induction with urinary FSH or recombinant FSH in PCOS patients: a prospective randomized analysis of cost effectiveness. Reproductive BioMedicine Online 9, 494-499.
21. Gougeon A 1986 Dynamics of follicular growth in the human: a model from preliminary results. Human Reproduction 1, 81-87.
22. Homburg R, Howles CM 1999 Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Human Reproduction Update 5, 493-499.
23. Huhtaniemi I, Pettersson K 1998 Mutations and polymorphisms in the gonadotrophin genes; clinical relevance. Clinical Endocrinology (Oxford) 48, 675-682.
24. Josso N, di Clemente N 1999 TGF-beta family members and gonadal development. Trends In Endocrinology and Metabolism 10, 216-222.
25. Kamrava MM, Seibel MM, Berger MJ et al. 1982 Reversal of persistent anovulation in polycystic ovarian disease by administration of chronic low-dose follicle-stimulating hormone. Fertility and Sterility 37, 520-523.
26. Kolibianakis EM, Albano C, Camus M et al. 2004a Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertility and Sterility 82, 102-107.
27. Kolibianakis EM, Zikopoulos K, Schiettecatte J et al. 2004b Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Human Reproduction 19, 2490-2496.
28. Ludwig M, Rabe T, Buhler K et al. 2004 Efficacy of recombinant human FSH in comparison with urinary hMG following a long protocol down-regulation - an analysis of 24,764 ART cycles in Germany. Journal für Reproduction und Endokrinologie 4, 1-5.
29. Macklon NS, Fauser BC 2002 The step-down protocol. In: Tarlatzis B (ed.) Ovulation Induction. Elsevier, Paris, pp. 108-118.
30. Matthews CH, Borgato S, Beck-Peccoz P et al. 1993 Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nature Genetics 5, 83-86.
31. Moreno L, Diaz I, Pacheco A et al. 2004 Extended coasting duration exerts a negative impact on IVF cycle outcome due to premature luteinization. Reproductive BioMedicine Online 9, 500-504.
32. National Institute for Clinical Excellence (UK) 2004 Fertility: assessment and treatment for people with fertility problems. Clinical Guideline 11.
33. Oelsner G, Serr DM, Mashiach S et al. 1978 The study of induction of ovulation with menotropins: analysis of results of 1897 treatment cycles. Fertility and Sterility 30, 538-544.
34. Olivennes F, Belaisch-Allart, J, Emperaire JC et al. 2000 Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LHRH) antagonist (cetrorelix) or a depot formula of an LHRH agonist (triptorelin). Fertility and Sterility 73, 314-320.
35. Out HJ, Rutherford A, Fleming R et al. 2004 Randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction 19, 90-95.
36. Polson DW, Mason HD, Saldahna MB, Franks S 1987 Ovulation of a single dominant follicle during treatment with low-dose pulsatile follicle stimulating hormone in women with polycystic ovary syndrome. Clinical Endocrinology (Oxford) 26, 205-212.
37. Sagle MA, Hamilton-Fairley D, Kiddy DS, Franks S 1991 A comparative, randomized study of low-dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome. Fertility and Sterility 55, 56-60.
38. Schoot DC, Coelingh Bennink HJ, Mannaerts BM et al. 1992 Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency. Journal of Clinical Endocrinology and Metabolism 74, 1471-1473.
39. Tadokoro N, Vollenhoven B, Clark S et al. 1997 Cumulative pregnancy rates in couples with anovulatory infertility compared with unexplained infertility in an ovulation induction programme. Human Reproduction 12, 1939-1944.
40. van Santbrink EJ, Donderwinkel PF, van Dessel TJ, Fauser BC 1995 Gonadotrophin induction of ovulation using a step-down dose regimen: single centre clinical experience in 82 patients. Human Reproduction 10, 1048-1053.
41. van Wely M, Bayram N, van der Veen F 2003 Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Human Reproduction 18, 1143-1149.
42. Vassart G, Pardo L, Costagliola S 2004 A molecular dissection of the glycoprotein hormone receptors. Trends in Biochemical Sciences 29, 119-126.
43. Wang CF, Gemzell C 1978 The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease. Fertility and Sterility 33, 479-486.
44. White DM, Polson DW, Kiddy D et al. 1996 Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. Journal of Clinical Endocrinology and Metabolism 81, 3821-3824.
45. Wikland M, Bergh C, Borg K et al. 2001 A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Human Reproduction 16, 1676-1681.
46. Yan C, Matzuk MM 2001 Transgenic models of ovarian failure. Journal of the Society for Gynecologic Investigation 8, S30-33.
47. Yarali H, Zeyneloglu HB 2004 Gonadotrophin treatment in patients with polycystic ovary syndrome. Reproductive BioMedicine Online 8, 528-537.
48. Yding Andersen C, Westergaard L G, van Wely M 2004 FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect? Reproductive BioMedicine Online 9, 231-236.